Boston, Massachusetts 02115


Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of graft failure. Novel therapies are urgently needed to reduce proteinuria and prevent graft loss in transplant recipients, since ACE inhibitors carry a number of limitations in the transplant setting, including significant reduction in renal function, anemia and hyperkalemia. Preliminary data: B7-1 is expressed at significant levels in about 10% of kidney allograft biopsies with predominance in patients with proteinuria. Hypothesis: We hypothesize that B7-1 targeting therapy may reduce proteinuria and improve graft survival in proteinuric transplant recipients that have B7-1 staining on allografts. In addition, the absence of CNI nephrotoxicity and the potential protective effect of Belatacept on DSA production may be of benefit in this subset of transplant patients. Objectives: Primary: Determine the effect of Belatacept conversion in reducing proteinuria by 25% at 12 months in renal transplant recipients (≥1gram/d) that are either B7-1-positive or negative on kidney biopsy. Secondary: Assess the effect of Belatacept conversion in the percent change of renal function from baseline to 12 months; donor-specific anti-HLA antibodies presence and intensity (MFI); correlation of B7-1 positivity on immunofluorescence on biopsy with B7-1-expression in urine extracellular vesicles; adverse events; acute rejection episodes; blood pressure control; new onset diabetes; hyperlipidemia; graft survival; and patient survival.

Study summary:

A total of 36 patients will be recruited.


Inclusion Criteria: 1. Male or female adult kidney transplant recipients older than 18 years old 2. eGFR ≥30 ml/min 3. ≥6 months after transplantation 4. Proteinuria ≥1 gram/day in spot urine protein/creatinine ratio 5. Ability to provide written informed consent for the study. 6. Maintenance immunosuppression of CNI (cyclosporine or tacrolimus), antiproliferative agent (azathioprine, MMF or MPA) with either steroids or not. Exclusion Criteria: 1. Age <18 years 2. eGFR<30 ml/min 3. active acute cellular rejection (ACR; higher than borderline) or ACR in the previous 6 months; active acute antibody-mediated rejection 4. recurrent FSGS 5. EBV IgG negative 6. patient on mTOR inhibitor (e.g. Everolimus, Sirolimus) 7. patient only on CNI (cyclosporine or tacrolimus) and steroids



Primary Contact:

Principal Investigator
Leonardo V Riella, MD, PhD
Brigham and Women's Hospital

Leonardo V Riella, MD, PhD
Phone: 617-732-5852

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

Leonardo V Riella
Phone: 617-732-5852

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.